Stockscreener 앱 받기
8.38
3.29%
-0.285
시간 외 거래:
8.54
0.16
+1.91%
전일 마감가:
$8.665
열려 있는:
$8.44
하루 거래량:
733.89K
Relative Volume:
0.61
시가총액:
$452.84M
수익:
$2.80M
순이익/손실:
$-122.23M
주가수익비율:
-3.669
EPS:
-2.284
순현금흐름:
$-46.53M
1주 성능:
-11.18%
1개월 성능:
-1.87%
6개월 성능:
-48.84%
1년 성능:
-1.99%
1일 변동 폭
$8.2303
$8.63
1주일 범위
$8.2303
$9.90
52주 변동 폭
$5.14
$33.68
Upstream Bio Inc Stock (UPB) Company Profile
명칭
Upstream Bio Inc
전화
781-208-2466
주소
890 WINTER STREET, SUITE 200, WALTHAM
Compare UPB vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
UPB
Upstream Bio Inc
|
8.38 | 468.24M | 2.80M | -122.23M | -46.53M | -2.284 |
|
VRTX
Vertex Pharmaceuticals Inc
|
458.05 | 114.72B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
737.45 | 78.67B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
684.50 | 42.38B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
311.10 | 41.75B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
282.72 | 31.33B | 5.36B | 287.73M | 924.18M | 2.5229 |
Upstream Bio Inc Stock (UPB) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-18 | 개시 | Mizuho | Outperform |
| 2025-11-18 | 개시 | Evercore ISI | Outperform |
| 2025-10-14 | 개시 | Truist | Buy |
| 2024-11-05 | 개시 | JP Morgan | Overweight |
| 2024-11-05 | 개시 | Piper Sandler | Overweight |
| 2024-11-05 | 개시 | TD Cowen | Buy |
| 2024-11-05 | 개시 | William Blair | Outperform |
모두보기
Upstream Bio Inc 주식(UPB)의 최신 뉴스
UPB | Upstream Bio, Inc. Common Insider Trading - Quiver Quantitative
Upstream Bio CFO Gray sells $7915 in shares - Investing.com
Upstream Bio CEO Makes Notable Move With Fresh Stock Sale - TipRanks
Risk Recap: Whats next for Upstream Bio Inc stockM&A Rumor & Short-Term Swing Trade Alerts - baoquankhu1.vn
Integral Health Asset Management LLC Acquires New Stake in Upstream Bio, Inc. $UPB - MarketBeat
Analysts Offer Insights on Healthcare Companies: Upstream Bio, Inc. (UPB), TScan Therapeutics (TCRX) and Teladoc (TDOC) - The Globe and Mail
UPB Stock Price, Quote & Chart | UPSTREAM BIO INC (NASDAQ:UPB) - ChartMill
Upstream Bio (NASDAQ:UPB) Trading 14.4% HigherShould You Buy? - MarketBeat
UPB: Phase II data support quarterly dosing for verekitug, with phase III and COPD programs advancing - TradingView
UPB: Verekitug's quarterly dosing shows robust efficacy, with phase 3 and COPD programs advancing - TradingView
Upstream Bio, Inc. CEO joins Leerink Partners fireside chat at global healthcare conference - Traders Union
Dip Buying: Is Upstream Bio Inc forming a breakout pattern2025 Stock Rankings & Fast Entry High Yield Stock Tips - baoquankhu1.vn
Upstream Bio's selloff may be 'overdone,' but analyst highlights asthma drug's competitive edge concerns - MSN
Aug Sectors: Can Upstream Bio Inc deliver consistent dividendsJuly 2025 Outlook & Community Verified Watchlist Alerts - baoquankhu1.vn
Lifesci Capital Forecasts Upstream Bio Q2 Earnings - MarketBeat
Brokerages Set Upstream Bio, Inc. (NASDAQ:UPB) Price Target at $45.25 - Defense World
Why Did UPB Stock Plunge 40% Today? - Stocktwits
RSI Check: Can Upstream Bio Inc outperform in the next rallyWeekly Trade Summary & Weekly Chart Analysis and Guides - baoquankhu1.vn
UPB: Verekitug shows best-in-class efficacy and safety, advancing to phase 3 with quarterly dosing - TradingView
CEO Rand Sutherland hosts live conference fireside chat, Upstream Bio, Inc. asserts - Traders Union
Upstream Bio (UPB) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat
Upstream Bio, Inc. (NASDAQ:UPB) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Analysts Offer Insights on Healthcare Companies: Aardvark Therapeutics, Inc. (AARD), Upstream Bio, Inc. (UPB) and Cogent Biosciences (COGT) - The Globe and Mail
Upstream Bio presents additional Phase 2 data for verekitug - Investing.com South Africa
Upstream Bio presents additional Phase 2 data for verekitug By Investing.com - Investing.com Canada
Upstream Bio, Inc. unveils new analyses from VIBRANT Phase 2 trial at AAAAI2026 - Traders Union
Upstream Bio says primary endpoint showed reduction of -1.95 in nasal polyp score - marketscreener.com
Upstream Bio Says Primary Endpoint Showed Reduction of -1.95 in Nasal Polyp Score - TradingView
Upstream Bio Presents Additional Analyses from the Phase 2 - GlobeNewswire
UPB Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Upstream Bio, Inc. (UPB) Stock Analysis: Exploring a 505% Potential Upside in the Biotech Sector - DirectorsTalk Interviews
Upstream Bio to present verekitug CRSwNP trial data at AAAAI By Investing.com - Investing.com Australia
Upstream Bio to present verekitug CRSwNP trial data at AAAAI - Investing.com
Upstream Bio to Present Additional Analyses from Phase 2 VIBRANT Trial in Chronic Rhinosinusitis with Nasal Polyps in Late-Breaking Session at AAAAI Annual Meeting 2026 - Bitget
Upstream Bio to Present Additional Analyses from Phase 2 - GlobeNewswire
UPB Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
UPBUpStream Bio Inc. Latest Stock News & Market Updates - Stock Titan
Upstream Bio to Participate in Investor Conferences in March 2026 - geneonline.com
Peering Into Upstream Bio Inc's Recent Short Interest - Benzinga
Upstream Bio announces participation in major healthcare conferences - Traders Union
Upstream Bio to Participate in Upcoming March Investor Conferences - GlobeNewswire
Insider Trends: Is Upstream Bio Inc a defensive stockTrade Entry Summary & Community Driven Trade Alerts - baoquankhu1.vn
Can Upstream Bio Inc. ride the EV waveJuly 2025 Rallies & Expert Approved Momentum Ideas - mfd.ru
What are the risks of holding Upstream Bio Inc.2025 Sector Review & Reliable Intraday Trade Plans - mfd.ru
Is Upstream Bio Inc. stock suitable for long term investing2025 Geopolitical Influence & Reliable Price Breakout Alerts - mfd.ru
Upstream Bio down despite mid-stage trial win for asthma drug - MSN
Upstream Bio crashes after asthma drug succeeds — with the wrong dose - MSN
S P Trends: Is Upstream Bio Inc forming a bullish divergenceJuly 2025 Gainers & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Upstream Bio Shares Phase II VALIANT Data: Verekitug Cuts Severe Asthma Exacerbations Up to 56% - Defense World
Companies Like Upstream Bio (NASDAQ:UPB) Are In A Position To Invest In Growth - Yahoo Finance
Can Upstream Bio Inc. stock reach $100 price targetJuly 2025 Institutional & Technical Buy Zone Confirmations - mfd.ru
Upstream Bio Inc (UPB) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.20%
0.06%
자본화:
|
볼륨(24시간):